 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1997 | Volume 126 Issue 1 | Pages 63-73
Purpose: To review the literature on the effects of amiodarone on thyroid physiology and management of amiodarone-induced thyroid disease.
Data Sources: English-language articles identified through a MEDLINE search (for 1975 to 1995, using the terms amiodarone and thyroid) and selected cross-referenced articles.
Study Selection: Articles on the effects of amiodarone on thyroid physiology and function tests and occurrence, recognition, and management of amiodarone-induced thyroid disease.
Data Extraction: Data were manually extracted from selected studies and reports; emphasis was placed on information relevant to the practicing clinician.
Data Synthesis: Amiodarone can have many effects on thyroid function test results, even in the absence of hyperthyroidism or hypothyroidism. It may cause an increase in serum levels of thyroxine, reverse triiodothyronine, and thyroid-stimulating hormone and a decrease in serum triiodothyronine levels. Thyrotoxicosis occurs in some patients and is related to several pathogenetic mechanisms. It often presents dramatically with obvious clinical manifestations and further changes in thyroid function test results. Medical options include therapy with thionamides, perchlorate, and prednisone. Radioactive iodine is of little use. Thyroidectomy is effective and is the only measure that consistently allows continued use of amiodarone. Unlike thyrotoxicosis, hypothyroidism is related to a persistent Wolff-Chaikoff effect and often has a vague presentation. The goal of treatment of amiodarone-induced hypothyroidism is to bring serum thyroxine levels to the upper end of the normal range, as often seen in euthyroid patients who are receiving amiodarone.
Conclusions: Thyroid dysfunction commonly occurs with amiodarone therapy. It may be difficult to recognize the dysfunction because of the many changes in thyroid function test results that occur in euthyroid patients who are receiving amiodarone. Effective strategies exist for the management of hyperthyroidism and hypothyroidism; these should be tailored to the needs of the individual patient.
Author and Article Information
From Alton Ochsner Medical Foundation, New Orleans, Louisiana; and the Cleveland Clinic Foundation, Cleveland, Ohio.
REVIEW
Effects of Amiodarone on Thyroid Function
Requests for Reprints: Kishore J. Harjai, MD, 113 Betz Avenue, Jefferson, LA 70121.
Current Author Addresses: Dr. Harjai: 113 Betz Avenue, Jefferson, LA 70121.
This article has been cited by other articles:
|
|
 |
|
  C. van Noord, W. M van der Deure, M. C J M Sturkenboom, S. M J M Straus, A. Hofman, T. J Visser, J. A Kors, J. C M Witteman, and B. H C. Stricker High free thyroxine levels are associated with QTc prolongation in males J. Endocrinol., July 1, 2008; 198(1): 253 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Vassallo and R. G. Trohman Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications JAMA, September 19, 2007; 298(11): 1312 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Waldhauser, M. Torok, H.-R. Ha, U. Thomet, D. Konrad, K. Brecht, F. Follath, and S. Krahenbuhl Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone Derivatives J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1413 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J O'Sullivan, M. Lewis, and T. Diamond Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur. J. Endocrinol., April 1, 2006; 154(4): 533 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kahaly and W. H. Dillmann Thyroid Hormone Action in the Heart Endocr. Rev., August 1, 2005; 26(5): 704 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Pearce, A. P. Farwell, and L. E. Braverman Thyroiditis N. Engl. J. Med., June 26, 2003; 348(26): 2646 - 2655. [Full Text] [PDF]
|
|
|
|
 |
|
 A. PINTO and M. GLICK Management of patients with thyroid disease: Oral health considerations J Am Dent Assoc, July 1, 2002; 133(7): 849 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Bianco, D. Salvatore, B. Gereben, M. J. Berry, and P. R. Larsen Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases Endocr. Rev., February 1, 2002; 23(1): 38 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Intenzo, D. M. Capuzzi, S. Jabbour, S. M. Kim, and A. E. dePapp Scintigraphic Features of Autoimmune Thyroiditis RadioGraphics, July 1, 2001; 21(4): 957 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Martino, L. Bartalena, F. Bogazzi, and L. E. Braverman The Effects of Amiodarone on the Thyroid Endocr. Rev., April 1, 2001; 22(2): 240 - 254. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Negro, D. Dazzi, and A. Pezzarossa The management of thyroid disease by GPs Fam. Pract., April 1, 2001; 18(2): 195 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Klein and K. Ojamaa Thyroid Hormone and the Cardiovascular System N. Engl. J. Med., February 15, 2001; 344(7): 501 - 509. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Di Matola, F. D’Ascoli, G. Fenzi, G. Rossi, E. Martino, F. Bogazzi, and M. Vitale Amiodarone Induces Cytochrome c Release and Apoptosis through an Iodine-Independent Mechanism J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4323 - 4330. [Abstract] [Full Text]
|
|
|
|
 |
|
 G E Kochiadakis, N E Igoumenidis, M E Marketou, M D Kaleboubas, E N Simantirakis, and P E Vardas Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study Heart, September 1, 2000; 84(3): 251 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J H Lazarus and K Obuobie Thyroid disorders---an update Postgrad. Med. J., September 1, 2000; 76(899): 529 - 536. [Full Text]
|
|
|
|
 |
|
 K. A. Woeber Update on the Management of Hyperthyroidism and Hypothyroidism Arch Fam Med, August 1, 2000; 9(8): 743 - 747. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Goldschlager, A. E. Epstein, G. Naccarelli, B. Olshansky, B. Singh, and for the Practice Guidelines Subcommittee, North Am Practical Guidelines for Clinicians Who Treat Patients With Amiodarone Arch Intern Med, June 26, 2000; 160(12): 1741 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Woeber Update on the Management of Hyperthyroidism and Hypothyroidism Arch Intern Med, April 24, 2000; 160(8): 1067 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-C. Loh Current concepts in medicine: Amiodarone-induced thyroid disorders: a clinical review Postgrad. Med. J., March 1, 2000; 76(893): 133 - 140. [Abstract] [Full Text]
|
|
|
|
|
|
P. F Findlay and D G Seymour Hyperthyroidism in an elderly patient Postgrad. Med. J., March 1, 2000; 76(893): 173 - 175. [Full Text]
|
|
|
|
 |
|
 A. E. Hak, H. A.P. Pols, T. J. Visser, H. A. Drexhage, A. Hofman, and J. C.M. Witteman Subclinical Hypothyroidism Is an Independent Risk Factor for Atherosclerosis and Myocardial Infarction in Elderly Women: The Rotterdam Study Ann Intern Med, February 15, 2000; 132(4): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vitale, T. Di Matola, F. D'Ascoli, S. Salzano, F. Bogazzi, G. Fenzi, E. Martino, and G. Rossi Iodide Excess Induces Apoptosis in Thyroid Cells through a p53-Independent Mechanism Involving Oxidative Stress Endocrinology, February 1, 2000; 141(2): 598 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F W F Hanna, J H Lazarus, and M F Scanlon Fortnightly review: Controversial aspects of thyroid disease BMJ, October 2, 1999; 319(7214): 894 - 899. [Full Text]
|
|
|
|
 |
|
 S. A. Thorne, I. Barnes, P. Cullinan, and J. Somerville Amiodarone-Associated Thyroid Dysfunction : Risk Factors in Adults With Congenital Heart Disease Circulation, July 13, 1999; 100(2): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wolff Perchlorate and the Thyroid Gland Pharmacol. Rev., March 1, 1998; 50(1): 89 - 106. [Abstract] [Full Text] [PDF]
|
|
Article
